Table 2. Characteristics of Patients With Cancer and Treatment Regimens.
| Variable | Patients, No. (%) | P value | ||
|---|---|---|---|---|
| Breast cancer (n = 513) | HL (n = 71) | NHL (n = 228) | ||
| First line chemotherapy regimen | ||||
| Anthracycline | 430 (84) | 68 (96) | 164 (72) | <.001 |
| Not anthracyclines | 70 (14) | 3 (4) | 64 (28) | |
| Trastuzumab | 13 (3) | 0 | 0 | |
| Radiation | 343 (67) | 21 (30) | 4 (2) | <.001 |
| Right breast or chest wall radiation | 173 (34) | 0 | 0 | <.001 |
| Left breast or chest wall radiation | 175 (34) | 1 (1) | 0 | <.001 |
| Mediastinal radiation | 1 (<1) | 20 (28) | 4 (2) | <.001 |
| Anthracycline dose, mg/m2 | ||||
| Nonea | 83 (16) | 3 (4) | 64 (28) | <.001 |
| <180 | 20 (4) | 10 (14) | 43 (19) | |
| 180-250 | 370 (72) | 20 (28) | 22 (10) | |
| >250 | 40 (8) | 38 (54) | 99 (43) | |
| Treatment at cancer diagnosis | ||||
| β-blocker | 48 (9) | 3 (4) | 47 (21) | <.001 |
| ACEI or ARBs | 48 (9) | 4 (6) | 49 (22) | <.001 |
| Statins | 50 (10) | 3 (4) | 38 (17) | .003 |
Abbreviations: ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma.
a
No anthracycline therapy included patients who were treated with trastuzumab.